SCHEMBL29636816

SCHEMBL29636816

COc1ccc(-c2cc(NCCCNCCCO)c3ccccc3n2)cc1

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 14/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23015148 1.00 ACP1 (0.68) ACP1
SCHEMBL23015177 0.96 ACP1 (0.73) ACP1
SCHEMBL29636757 0.90 ACP1 (0.66) ACP1
SCHEMBL23015121 0.89 ACP1 (0.68) ACP1
SCHEMBL29636697 0.89 ACP1 (0.68) ACP1
SCHEMBL29636806 0.89 ACP1 (0.68) ACP1
SCHEMBL23015124 0.89 ACP1 (0.68) ACP1
SCHEMBL23015370 0.89 ACP1 (0.64) ACP1
Hydrochloric Acid SCHEMBL23015090 0.88 ACP1 (0.67) ACP1
Hydrochloric Acid SCHEMBL29636794 0.88 ACP1 (0.67) ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 EP disclosed